Stock Information
symbol line chart

PLSEPulse Biosciences Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Kevin Danahy

Location

California, USA

Exchange

Nasdaq

Website

https://pulsebiosciences.com

Summary

Pulse Biosciences, Inc.

Company Info

CEO

Kevin Danahy

Location

California, USA

Exchange

Nasdaq

Website

https://pulsebiosciences.com

Summary

Pulse Biosciences, Inc.

AI Insights for PLSE
2 min read

Quick Summary

Pulse Biosciences Inc is a medical device company focused on developing and commercializing novel bioelectric medicine technologies. The company is primarily known for its Nano-Pulse Stimulation (NPS) technology, which delivers ultrashort electrical pulses to targeted cells for nonthermal tissue ablation. Pulse Biosciences has pivoted its attention to fields such as cardiac surgery and oncology, with its products intended for hospitals and healthcare providers treating patients with conditions like atrial fibrillation and benign thyroid nodules. The firm also works with research institutions such as MD Anderson Cancer Center to further develop and validate its ablation treatments. Pulse Biosciences is headquartered in Hayward, California and is led by CEO Kevin Danahy.

The Bull Case

  • Pulse Biosciences’ leading-edge Nano-Pulse Stimulation and nanosecond Pulsed Field Ablation technologies differentiate its devices from thermal ablation competitors, offering potential safety and healing advantages.
  • The company has demonstrated an ability to navigate FDA processes and gained key approvals to further its clinical programs.
  • Strategic relationships with top-tier medical research institutions enhance its credibility and expand its pipeline opportunities.
  • Its substantial cash position and recent financing provide runway for continued development.
  • The team’s willingness to pivot and focus on higher-impact markets, such as cardiac ablation and oncology, is a sign of adaptive strategic thinking.

The Bear Case

  • The company’s commercial adoption is at an early stage, with negligible revenues compared to high R&D and operating costs, which continue to generate substantial net losses.
  • Pulse Biosciences’ products face regulatory uncertainty and long, costly approval processes, which could delay or limit adoption.
  • Funding for future studies and operations is heavily reliant on debt and external financing, raising financial risk.
  • The company has limited market share and track record compared to entrenched competitors.
  • Organizational changes and staff reductions in certain divisions could impact operational efficiency and morale.

Key Risks

  • The company faces ongoing risks from high cash burn and operating expenses, which may necessitate further dilution or debt if revenue growth does not materialize.
  • There is regulatory and clinical uncertainty as products undergo trials and FDA review, with the possibility of setbacks or failures.
  • Competition from larger, well-funded medical device companies could limit Pulse Biosciences’ ability to gain market share.
  • Commercial adoption may be slow if healthcare providers are reluctant to switch from established ablation methods or if insurance reimbursement is lacking.

What to Watch

UpcomingDuring the most recent quarter, Pulse Biosciences achieved significant regulatory progress, receiving FDA IDE approval to begin clinical trials for its nPulse Cardiac Ablation System targeting paroxysmal atrial fibrillation.
UpcomingRevenue was reported at $86,000, while net losses deepened due to increased operating and development costs.
UpcomingThe company also initiated a strategic research partnership with MD Anderson Cancer Center to study its nPulse Vybrance device for thyroid tumor ablation.
ExpectedIn the upcoming quarter, Pulse Biosciences is expected to continue enrolling patients in its FDA-approved cardiac and thyroid ablation trials, expanding the clinical use of its pulsed field technology.

Price Drivers

  • The company’s stock price is primarily driven by regulatory milestones, such as FDA approvals and progress in clinical trials for its ablation systems.
  • Early commercialization efforts and adoption rates in both the U.S.
  • and Europe impact investor sentiment.
  • High R&D expenses and net losses versus initial but modest revenues are key financial factors.

Recent News

  • Pulse Biosciences received multiple FDA approvals to begin human clinical trials for its nPulse Cardiac Catheter Ablation System and its Vybrance device for thyroid tumor ablation.
  • The company launched a high-profile research partnership with MD Anderson Cancer Center.
  • Leadership changes included naming Kevin Danahy as CEO, while former CEO Darrin Uecker became CTO.
  • The company secured a $65 million loan to support ongoing product development and is exploring new dermatology partnerships while cutting staff in that division.

Market Trends

  • There is a growing market demand for minimally invasive and nonthermal ablation treatments, particularly in cardiology and oncology.
  • Regulatory pathways for novel energy-based devices are becoming more defined, with the FDA providing fast-track opportunities for breakthrough therapies.
  • Major competitors are aggressively investing in pulsed field ablation and electric field technologies, intensifying competition as new entrants and established players vie for market share.
  • Healthcare providers are increasingly interested in devices that offer rapid recovery, minimal collateral tissue damage, and workflow efficiency.

AI-generated summary. Not investment advice. DYOR.

Community Research

Research from investors like you

Be the first to share your analysis on PLSE

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show